Erratum: MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer (Cell Death and Disease (2015), 6, 10.1038/cddis.2015.200);MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Zhang, Y ^a,b   Talmon, G ^c   Wang, J ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; FLUOROURACIL; ISOPROTEIN; MICRORNA; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC ANTIMETABOLITE; FUSED HETEROCYCLIC RINGS; MIRN587 MICRORNA, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R1B PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; XIAP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938885395     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.450     Document Type: Erratum

References (60)

1. Heidelberger C, Chaudhuri N, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
3. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006; 1766: 184-196.
4. Liu Y-Y, Han T-Y, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001; 15: 719-730.
5. Longley D, Johnston P. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
6. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7: 584-590.
7. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-627.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
9. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
10. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355.
11. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
12. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
13. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
14. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
15. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
16. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997; 272: 31515-31524.
17. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998; 17: 313-325.
18. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF et al. Dual role of phosphatidylinositol-3, 4, 5-trisphosphate in the activation of protein kinase B. Science 1997; 277: 567-570.
19. Beaulieu J-M, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/?-Arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-273.
20. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013; 14: e229-e238.
21. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-34090.
22. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007; 27: 17-28.
23. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang H-G et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412.
24. Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. J Biol Chem 2011; 286: 37368-37378.
25. Opel D, Naumann I, Schneider M, Bertele D, Debatin K-M, Fulda S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res 2011; 17: 3233-3247.
26. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007; 67: 1430-1435.
27. Baysal BE, Willett-Brozick JE, Taschner P, Dauwerse J, Devilee P, Devlin B. A highresolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region. Eur J Hum Genet 2001; 9: 121-129.
28. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998; 282: 284-287.
29. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, Saji S. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000; 47: 268-271.
30. Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001; 20: 1892-1899.
31. Tamaki M, Goi T, Hirono Y, Katayama K, Yamaguchi A. PPP2R1B gene alterations inhibit interaction of PP2A-A? and PP2A-C proteins in colorectal cancers. Oncol Rep 2004; 11: 655-659.
32. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kähäri V-M, Heino J. Integrin ?2?1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3?. Mol Cell Biol 2002; 22: 1352-1359.
33. Li G, Ji X-D, Gao H, Zhao J-S, Xu J-F, Sun Z-J et al. EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat Commun 2012; 3: 667.
34. Kuo Y-C, Huang K-Y, Yang C-H, Yang Y-S, Lee W-Y, Chiang C-W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55? regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 2008; 283: 1882-1892.
35. Gayet J, Zhou X-P, Duval A, Rolland S, Hoang J-M, Cottu P et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 2001; 20: 5025-5032.
36. Lim HK, Bae W, Lee HS, Jung J. Anticancer activity of marine sponge Hyrtios sp. extract in human colorectal carcinoma RKO cells with different p53 status. Biomed Res Int 2014; 413575: 27.
37. Zhang Y, Geng L, Talmon G, Wang J. MicroRNA-520 g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 2015; 290: 6215-6225.
38. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci 2010; 107: 21098-21103.
39. Grimson A, Farh KK-H, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91-105.
40. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nature genetics 2005; 37: 495-500.
41. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010; 11: R90.
42. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2 A. Trends Biochem Sci 1999; 24: 186-191.
43. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-182.
44. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-2949.
45. Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, Weber HR et al. Identification of a novel TGF?/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One 2011; 6: e19335.
46. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
47. Yang J, Wu Z, Renier N, Simon DJ, Uryu K, Park DS et al. Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 2015; 160: 161-176.
48. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013; 24: 766-776.
49. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
50. Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu X-Q et al. Transforming growth factor ? induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 2008; 68: 3152-3160.
51. Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, Conway A et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther 2007; 6: 1143-1150.
52. Whang YE, Yuan X-J, Liu Y, Majumder S, Lewis TD. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam Horm 2004; 67: 409-426.
53. Kang KH, Kim WH, Choi KH. p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp Cell Res 1999; 253: 403-412.
54. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-7425.
55. Miyamoto M, Takano M, Iwaya K, Shinomiya N, Kato M, Aoyama T et al. X-chromosomelinked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer 2014; 110: 2881-2886.
56. Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S et al. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem 2013; 288: 23740-23750.
57. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008; 13: 259-271.
58. Liu J, Ji W, Sun S, Zhang L, Chen HG, Mao Y et al. The PP2A-A? gene is regulated by multiple transcriptional factors including Ets-1, SP1/SP3, and RXR?/?. Curr Mol Med 2012; 12: 982-994.
59. Boyd D, Levine A, Brattain D, McKnight M, Brattain M. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res 1988; 48: 2469-2474.
60. Geng L, Chaudhuri A, Talmon G, Wisecarver J, Are C, Brattain M et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 2013; 33: 5332-5340.